👀 Copy Legendary Investors' Portfolios in One ClickCopy For Free

TD Cowen maintains Buy on Symbotic, keeps $50 target

Published 27/11/2024, 20:12
SYM
-

On Wednesday, TD Cowen sustained its Buy rating on Symbotic Inc. (NASDAQ:SYM) with a consistent price target of $50.00. The firm's stance comes despite recent market reactions which the analyst believes may be overstated. The commentary provided by the analyst suggests that while the current situation is understandable, there is an expectation that once issues are clearly defined and contained, there should be no significant change to the out-year estimates for the company.

The analyst noted that Symbotic has a 15-business-day period to file its 10-K, a comprehensive report of the company's financial performance. During this time, the stock could face continued pressure. The firm anticipates reassessing their model and price target for Symbotic as needed after the filing is complete and more information is available.

Symbotic, a company specializing in AI-enabled robotics solutions for supply chain automation, has recently come under scrutiny, leading to heightened market sensitivity. The analyst from TD Cowen expressed confidence that once the current issues are "appropriately ringfenced," the long-term financial projections for Symbotic would remain stable.

In other recent news, Symbotic Inc. has been the subject of several crucial developments. After discovering additional accounting errors, the company revised its financial projections for fiscal year 2024 and first-quarter fiscal year 2025, leading KeyBanc Capital Markets to downgrade its stock rating from 'Overweight' to 'Sector Weight'. Despite the accounting issues, KeyBanc maintains a positive outlook on Symbotic's long-term prospects due to its position in the autonomous warehouse solutions market.

DA Davidson also downgraded Symbotic shares from 'Buy' to 'Neutral' and revised the price target to $35 in response to these financial errors. However, TD Cowen, Deutsche Bank (ETR:DBKGn), and KeyBanc all increased their price targets for Symbotic, maintaining positive ratings on the stock.

Symbotic reported a 55% year-over-year increase in revenue for the fourth quarter, reaching $577 million, and concluded the fiscal year with a total revenue of $1.8 billion. The company has also started construction on a second GreenBox facility in Georgia and announced a partnership with Walmart (NYSE:WMT) Mexico, expected to add approximately $400 million to the company's backlog.

Symbotic anticipates a 40% year-over-year increase for the first quarter of 2025, supported by the acquisition of Veo Robotics.

InvestingPro Insights

To complement TD Cowen's analysis of Symbotic Inc. (NASDAQ:SYM), recent data from InvestingPro offers additional context to the company's financial situation and market performance. Despite the current scrutiny, Symbotic has demonstrated strong revenue growth, with a 54.84% increase over the last twelve months as of Q4 2024. This aligns with the InvestingPro Tip indicating that analysts anticipate sales growth in the current year.

The company's market capitalization stands at $13.74 billion, reflecting significant investor interest despite recent challenges. Symbotic's stock has shown remarkable short-term performance, with a 36.43% return over the last month and an impressive 74.81% return over the last three months. These figures support the InvestingPro Tip highlighting the stock's strong recent returns.

However, it's important to note that Symbotic is currently not profitable, with a negative operating income of $49.23 million over the last twelve months. This aligns with the InvestingPro Tip stating that the company has not been profitable over the last twelve months. Nevertheless, another InvestingPro Tip suggests that analysts predict the company will be profitable this year, which could explain TD Cowen's maintained Buy rating.

For investors seeking a more comprehensive analysis, InvestingPro offers 13 additional tips for Symbotic, providing a deeper understanding of the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.